Table 4.
Correlation of clinicopathological variables and molecular biomarkers with relapse-free survival (RFS) (univariate analysis)
| Variables | No. of patients (n = 683) (%) | 4-year RFS rate (%) | Hazard ratio | 95% confidence interval | P valuea |
|---|---|---|---|---|---|
| Age (years) | |||||
| <35 | 51 (7.5) | 78.6 | 3.19 | 1.611–6.318 | 0.0004 |
| ≥35 | 632 (92.5) | 93.2 | |||
| Type of surgery | |||||
| Breast-conserving surgery | 284 (41.6) | 90 | 0.589 | 0.351–0.986 | 0.0427 |
| Mastectomy | 399 (58.4) | 93.7 | |||
| Pathological tumor size | |||||
| <2 cm | 399 (58.5) | 93 | 0.595 | 0.355–0.996 | 0.0225 |
| ≥2 cm | 284 (41.5) | 89.5 | |||
| Endovascular or lymphatic tumor emboli | |||||
| (−) | 589 (86.2) | 93 | 0.483 | 0.260–0.896 | 0.018 |
| (+) | 90 (13.2) | 86.1 | |||
| Unknown | 4 (0.6) | ||||
| Close resection margin | |||||
| <3 mm | 678 (99.3) | 60 | 5.729 | 1.396–23.512 | 0.006 |
| ≥3 mm | 5 (0.7) | 92.4 | |||
| Histological grade | |||||
| 1 or 2 | 379 (55.5) | 92.8 | 0.658 | 0.376–1.150 | 0.1411 |
| 3 | 184 (26.9) | 87.9 | |||
| Unknown | 120 (17.6) | ||||
| Nuclear grade | |||||
| 1 or 2 | 421 (61.6) | 93 | 0.663 | 0.389–1.128 | 0.127 |
| 3 | 202 (29.6) | 88.5 | |||
| Unknown | 60 (8.8) | ||||
| Estrogen receptor | |||||
| (−) | 274 (40.1) | 87.4 | 2.609 | 1.535–4.435 | 0.0002 |
| (+) | 409 (59.9) | 95.4 | |||
| Progesterone receptor | |||||
| (−) | 410 (60.0) | 90.1 | 1.755 | 0.986–3.123 | 0.054 |
| (+) | 273 (40.0) | 95.3 | |||
| HER-2/neu | |||||
| Positive | 175 (25.6) | 92.5 | 1.015 | 0.559–1.840 | 0.712 |
| Undetermined | 123 (18) | 93 | 0.793 | 0.316–1.728 | |
| Negative | 385 (56.4) | 91.9 | |||
| Groups according to HR and HER-2/neu status | |||||
| Triple-negative | 136 (19.9) | 85.5 | 2.445 | 1.411–4.236 | 0.001 |
| Non-triple-negative | 529 (77.5) | 94.2 | |||
| HR-negative and HER-2/neu-undetermined | 18 (2.6) | ||||
| p53 | |||||
| <25% | 502 (73.5) | 92.7 | 0.729 | 0.417–1.275 | 0.2686 |
| ≥25% | 171 (25.0) | 90.8 | |||
| Unknown | 10 (1.5) | ||||
| Ki-67 | |||||
| <20% | 596 (87.3) | 93.3 | 0.422 | 0.223–0.799 | 0.0064 |
| ≥20% | 74 (10.8) | 83.2 | |||
| Unknown | 13 (1.9) | ||||
| B-cell lymphoma 2 | |||||
| (−) | 209 (30.6) | 87.1 | 2.249 | 1.338–3.781 | 0.0017 |
| (+) | 459 (67.2) | 94.5 | |||
| Unknown | 15 (2.2) | ||||
| Epidermal growth factor receptor | |||||
| (−) | 348 (51.0) | 92.4 | 1.726 | 0.234–12.726 | 0.5855 |
| (+) | 22 (3.2) | 94.7 | |||
| Unknown | 313 (45.8) | ||||
| Adjuvant chemotherapy | |||||
| None | 262 (38.4) | 94.3 | 0.645 | 0.366–1.135 | 0.1285 |
| Yes | 418 (61.2) | 90.8 | |||
| Unknown | 3 (0.4) | ||||
Note:
a
Based on log-rank test.
Abbreviations: HER-2, human epidermal growth factor receptor 2; HR, hormone receptor.